These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34657638)

  • 21. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
    CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study.
    McIntyre RS; Florea I; Pedersen MM; Christensen MC
    J Clin Psychiatry; 2023 May; 84(4):. PubMed ID: 37227402
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of vortioxetine for the treatment of major depressive disorder: a randomised double-blind placebo-controlled study.
    Wang J; Liu XF; Feng C; Bao Q; Fu HR
    Int J Psychiatry Clin Pract; 2019 Nov; 23(4):245-250. PubMed ID: 29113521
    [No Abstract]   [Full Text] [Related]  

  • 24. Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study.
    Christensen MC; Schmidt SN; Grande I
    J Affect Disord; 2023 Oct; 338():423-431. PubMed ID: 37315590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
    Berhan A; Barker A
    BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis.
    Jacobsen PL; Mahableshwarkar AR; Palo WA; Chen Y; Dragheim M; Clayton AH
    CNS Spectr; 2016 Oct; 21(5):367-378. PubMed ID: 26575433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
    J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.
    Liebowitz MR; Careri J; Blatt K; Draine A; Morita J; Moran M; Hanover R
    Depress Anxiety; 2017 Dec; 34(12):1164-1172. PubMed ID: 29166552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Alam MY; Jacobsen PL; Chen Y; Serenko M; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2014 Jan; 29(1):36-44. PubMed ID: 24169027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study.
    Adair M; Bose R; Schmidt SN
    Curr Med Res Opin; 2024 Sep; 40(9):1637-1645. PubMed ID: 39110846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study.
    Jacobsen P; Zhong W; Xu R; Nomikos G
    J Affect Disord; 2020 Apr; 266():173-181. PubMed ID: 32056873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study.
    Rancans E; Zambori J; Dalsgaard M; Baayen C; Areberg J; Ettrup A; Florea I
    Int Clin Psychopharmacol; 2020 Nov; 35(6):305-312. PubMed ID: 32784346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma.
    Christensen MC; Florea I; Loft H; McIntyre RS
    J Affect Disord; 2020 Feb; 263():258-266. PubMed ID: 31818787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
    McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
    J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study.
    Thase ME; Jacobsen PL; Hanson E; Xu R; Tolkoff M; Murthy NV
    J Affect Disord; 2022 Apr; 303():123-130. PubMed ID: 35131363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.
    Alvarez E; Perez V; Dragheim M; Loft H; Artigas F
    Int J Neuropsychopharmacol; 2012 Jun; 15(5):589-600. PubMed ID: 21767441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA; Loft H; Olsen CK
    J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
    Fagiolini A; Florea I; Loft H; Christensen MC
    J Affect Disord; 2021 Mar; 283():472-479. PubMed ID: 33516560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.